DE69432417D1 - Differentiell exprimierte leishmania gene und proteinen - Google Patents

Differentiell exprimierte leishmania gene und proteinen

Info

Publication number
DE69432417D1
DE69432417D1 DE69432417T DE69432417T DE69432417D1 DE 69432417 D1 DE69432417 D1 DE 69432417D1 DE 69432417 T DE69432417 T DE 69432417T DE 69432417 T DE69432417 T DE 69432417T DE 69432417 D1 DE69432417 D1 DE 69432417D1
Authority
DE
Germany
Prior art keywords
differentially expressed
proteins
leishmania
genes
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69432417T
Other languages
English (en)
Other versions
DE69432417T2 (de
Inventor
Gregory Matlashewski
Hugues Charest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University filed Critical McGill University
Application granted granted Critical
Publication of DE69432417D1 publication Critical patent/DE69432417D1/de
Publication of DE69432417T2 publication Critical patent/DE69432417T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/822—Protozoa

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69432417T 1993-09-03 1994-09-01 Differentiell exprimierte leishmania gene und proteinen Expired - Fee Related DE69432417T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US115987 1987-11-02
US11598793A 1993-09-03 1993-09-03
PCT/CA1994/000482 WO1995006729A1 (en) 1993-09-03 1994-09-01 Differentially expressed leishmania genes and proteins

Publications (2)

Publication Number Publication Date
DE69432417D1 true DE69432417D1 (de) 2003-05-08
DE69432417T2 DE69432417T2 (de) 2004-02-12

Family

ID=22364580

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69432417T Expired - Fee Related DE69432417T2 (de) 1993-09-03 1994-09-01 Differentiell exprimierte leishmania gene und proteinen

Country Status (9)

Country Link
US (4) US5733778A (de)
EP (1) EP0716697B1 (de)
JP (1) JPH09502091A (de)
AT (1) ATE236252T1 (de)
AU (1) AU7529194A (de)
DE (1) DE69432417T2 (de)
ES (1) ES2198420T3 (de)
PT (1) PT716697E (de)
WO (1) WO1995006729A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162638A (en) 1996-05-06 2000-12-19 Universite Laval Attenuated strains of leishmania and uses thereof
US6020144A (en) * 1996-09-12 2000-02-01 Symbiontics, Inc. Sustained delivery device comprising a Leishmania protozoa and methods of making and using the same
US6331304B1 (en) * 1996-09-13 2001-12-18 Universite Laval Macrophage-infecting parasites expressing a granulocyte macrophage colony stimulating factor
GB9706930D0 (en) 1997-04-04 1997-05-21 Univ Glasgow Leishmania vaccine
WO2000032796A2 (en) 1998-12-02 2000-06-08 University Of Georgia Research Foundation, Inc. Kinetoplastid protein expression system
US6673351B1 (en) 2001-03-16 2004-01-06 Astralis, Llc Compositions and methods for the treatment and clinical remission of psoriasis
US20040241168A1 (en) * 2001-03-16 2004-12-02 O'daly Jose A. Compositions and methods for the treatment and clinical remission of psoriasis
EP1372705A2 (de) * 2001-03-29 2004-01-02 McGILL UNIVERSITY Leishmania impfstoffe
BR0314629A (pt) 2002-09-19 2005-08-02 Us Gov Health & Human Serv Polipeptìdeos de p. ariasi polipeptìdeos de p. perniciosus e métodos e uso
BR0315872A (pt) 2002-10-29 2006-07-18 Us Gov Health & Human Serv Polipeptìdeos de lutzomyia longipalpis e processos de utilização e método de uso
WO2005021030A1 (en) * 2003-08-29 2005-03-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Live attenuated leishmania vaccines
FR2861740B1 (fr) 2003-10-29 2005-12-16 Inst Rech Developpement Ird Souches de protozoaire de virulence attenuee et leur utilisation
US20090028932A1 (en) * 2005-04-15 2009-01-29 Wilson Mary E Vaccine formulations for leishmania
US7833534B2 (en) 2006-04-10 2010-11-16 Infectious Disease Research Institute Compounds and methods for diagnosis and treatment of leishmaniasis
US8968749B2 (en) 2006-07-21 2015-03-03 Universidade Federal De Minas Gerais—Ufmg Vaccine composition and immunization method
BRPI0603490B1 (pt) * 2006-07-21 2018-04-24 Universidade Federal De Minas Gerais Vacina recombinante contra a leishmaniose visceral canina
BRPI0800485B8 (pt) * 2008-01-17 2021-05-25 Univ Minas Gerais vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
US8410258B2 (en) 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
AR073170A1 (es) * 2008-05-21 2010-10-20 Infectious Disease Res Inst Vacunas de poliproteinas recombinantes para el tratamiento y diagnostico de leishmaniasis
WO2009158729A2 (en) * 2008-06-27 2009-12-30 The Infectious Disease Research Institute Inc. Compounds and methods for diagnosis and treatment of chagas disease
US8231881B2 (en) 2008-07-03 2012-07-31 Infectious Disease Research Institute Fusion proteins and their use in the diagnosis and treatment of leishmaniasis
EP2141248B1 (de) * 2008-07-03 2012-12-12 Institut Pasteur Verfahren zur Identifizierung von Leishmania-Virulenzfaktoren
BR102013022374B1 (pt) * 2013-09-02 2022-04-19 Universidade Federal De Minas Gerais Gene modificado de leishmania ssp., processo para obtenção de proteína e uso como antígeno em composição vacinal ou em imunodiagnóstico
US11833197B2 (en) * 2018-02-13 2023-12-05 University Of Iowa Research Foundation Immunotherapy of leishmaniasis
ES2795149B2 (es) 2020-06-08 2022-07-04 Univ Madrid Complutense Quimera sintetica multiepitopica como vacuna y tratamiento frente a leishmaniosis en mamiferos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5047522A (en) * 1983-08-12 1991-09-10 Rockefeller University Isolated repetitive DNA of protozoan parasites
US4801530A (en) * 1984-02-29 1989-01-31 Rockefeller University Nucleotide hybridization assay for protozoan parasites
US4764370A (en) * 1984-09-12 1988-08-16 Scripps Clinic And Research Foundation Vaccine utilizing an avirulent strain of Salmonella typhimurium
WO1986002098A1 (fr) * 1984-10-01 1986-04-10 Institut Pasteur Anticorps monoclonaux anti-leishmania, hybridomes secreteurs de ces anticorps, antigenes de leishmania reconnus par ces anticorps, procede d'obtention et applications de ces anticorps monoclonaux et de ces antigenes
US4687666A (en) * 1985-02-19 1987-08-18 Ministerio De Sanidad Y Asistencia Social Instituto Venezolano De Investigationes Cientificas Vaccine for Leishmaniasis
US4908308A (en) * 1985-06-19 1990-03-13 The Trustees Of Columbia University In The City Of New York Method for detecting animal-infective protozoa in vitro and a method for detecting agents which block the differentiation thereof
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse

Also Published As

Publication number Publication date
US5827671A (en) 1998-10-27
ES2198420T3 (es) 2004-02-01
PT716697E (pt) 2003-08-29
US5780591A (en) 1998-07-14
EP0716697B1 (de) 2003-04-02
EP0716697A1 (de) 1996-06-19
DE69432417T2 (de) 2004-02-12
JPH09502091A (ja) 1997-03-04
ATE236252T1 (de) 2003-04-15
WO1995006729A1 (en) 1995-03-09
US6133017A (en) 2000-10-17
US5733778A (en) 1998-03-31
AU7529194A (en) 1995-03-22

Similar Documents

Publication Publication Date Title
ATE236252T1 (de) Differentiell exprimierte leishmania gene und proteinen
FR2514783B1 (fr) Interferon immunitaire humain
GR3029983T3 (en) Diagnosis of leishmaniasis.
DE69431060D1 (de) Klonierte glutaminsäure-decarboxylase
EP0251037A3 (en) Novel human tnf polypeptide mutants and dnas encoding said mutants
DE3586801D1 (de) Synthetische hepatitis-b-virus-vakzine die t-zellen- und b-zellenbestimmer enthalten.
GB9814538D0 (en) Helicobacter pylori bacterioferritin
CA2105538A1 (en) Differentially Expressed Leishmania Genes and Proteins
ES2006730A6 (es) Un metodo de preparar un peptido o polipeptido sintetico que presenta la antigenicidad de la totalidad o una parte de un antigeno de p. falciparum
GB2176191A (en) Antigens of plasmodium falciparum
NZ233328A (en) Polypeptides produced by hepatocytes infected with p. falciparum; nucleic acid probes
ATE70979T1 (de) Plasmodium-falciparum-antigene der intraerythrocytaeren phase, ihre reinigung sowie antigen- und antikoerperbestimmung und sie enthaltende malaria-impfstoffe.
DK145988D0 (da) Genteknologisk fremstillet 140 kd-antigen af plasmodium falciparum og dettes anvendelse
BR0208140A (pt) Polipeptìdeo, agente imunoterapêutico para o tratamento de psorìase, sequência de ácido nucléico isolada ou seu complemento, vetores de filamento único, e de filamento duplo, sequência de ácido nucléico isolada ou variante imunogênica da mesma, métodos para a produção de polipeptìdeos, e para o tratamento e a remissão clìnica de psorìase, e, célula hospedeira microbiana
KR920016593A (ko) 플라스모듐 팔시파룸 혈액-단계 항원, 이의 제조방법 및 용도

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee